As of 2024-12-11, the Intrinsic Value of Kinnate Biopharma Inc (KNTE) is
-11.94 USD. This KNTE valuation is based on the model Peter Lynch Fair Value.
With the current market price of 2.65 USD, the upside of Kinnate Biopharma Inc is
-550.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-11.94 USD
Intrinsic Value
KNTE Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-11.94 - -11.94 |
-11.94 |
-550.59% |
| P/E |
(51.68) - (48.29) |
(55.11) |
-2179.5% |
| DDM - Stable |
(12.14) - (26.67) |
(19.41) |
-832.3% |
| DDM - Multi |
(9.34) - (16.58) |
(12.01) |
-553.1% |
KNTE Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
125.00 |
| Beta |
3.98 |
| Outstanding shares (mil) |
47.17 |
| Enterprise Value (mil) |
68.00 |
| Market risk premium |
4.60% |
| Cost of Equity |
15.03% |
| Cost of Debt |
5.00% |
| WACC |
9.35% |